Chronic ablation of TRPV1-sensitive skeletal muscle afferents attenuates the muscle metaboreflex
- 14 July 2021
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 321 (3) , R385-R395
Abstract
Exercise intolerance is a hallmark symptom of cardiovascular disease and likely occurs via enhanced activation of muscle metaboreflex-induced vasoconstriction of the heart and active skeletal muscle which, thereby limits cardiac output and peripheral blood flow. Muscle metaboreflex vasoconstrictor responses occur via activation of metabolite-sensitive afferent fibers located in ischemic active skeletal muscle, some of which express transient receptor potential vanilloid 1 (TRPV1) cation channels. Local cardiac and intrathecal administration of an ultrapotent noncompetitive, dominant negative agonist resiniferatoxin (RTX) can ablate these TRPV1-sensitive afferents. This technique has been used to attenuate cardiac sympathetic afferents and nociceptive pain. We investigated whether intrathecal administration (L4–L6) of RTX (2 µg/kg) could chronically attenuate subsequent muscle metaboreflex responses elicited by reductions in hindlimb blood flow during mild exercise (3.2 km/h) in chronically instrumented conscious canines. RTX significantly attenuated metaboreflex-induced increases in mean arterial pressure (27 ± 5.0 mmHg vs. 6 ± 8.2 mmHg), cardiac output (1.40 ± 0.2 L/min vs. 0.28 ± 0.1 L/min), and stroke work (2.27 ± 0.2 L·mmHg vs. 1.01 ± 0.2 L·mmHg). Effects were maintained until 78 ± 14 days post-RTX at which point the efficacy of RTX injection was tested by intra-arterial administration of capsaicin (20 µg/kg). A significant reduction in the mean arterial pressure response (+45.7 ± 6.5 mmHg pre-RTX vs. +19.7 ± 3.1 mmHg post-RTX) was observed. We conclude that intrathecal administration of RTX can chronically attenuate the muscle metaboreflex and could potentially alleviate enhanced sympatho-activation observed in cardiovascular disease states.Keywords
Funding Information
- HHS | NIH | National Heart, Lung, and Blood Institute (055473)
- HHS | NIH | National Heart, Lung, and Blood Institute (126706)
- HHS | NIH | National Heart, Lung, and Blood Institute (HL-120822)
- HHS | NIH | National Institute of General Medical Sciences (R25-GM058905)
This publication has 108 references indexed in Scilit:
- Antagonism of the TRPv1 receptor partially corrects muscle metaboreflex overactivity in spontaneously hypertensive ratsThe Journal of Physiology, 2011
- Implications of group III and IV muscle afferents for high‐intensity endurance exercise performance in humansThe Journal of Physiology, 2011
- Alteration in skeletal muscle afferents in rats with chronic heart failureThe Journal of Physiology, 2010
- Group III and IV muscle afferents contribute to ventilatory and cardiovascular response to rhythmic exercise in humansJournal of Applied Physiology, 2010
- Muscle metaboreflex-induced coronary vasoconstriction functionally limits increases in ventricular contractilityJournal of Applied Physiology, 2010
- Chronic femoral artery occlusion augments exercise pressor reflex in decerebrated ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Exercise training prevents the exaggerated exercise pressor reflex in rats with chronic heart failureJournal of Applied Physiology, 2010
- Autonomic control of heart rate by metabolically sensitive skeletal muscle afferents in humansThe Journal of Physiology, 2010
- The TRPv1 receptor is a mediator of the exercise pressor reflex in ratsThe Journal of Physiology, 2010
- Opioid‐mediated muscle afferents inhibit central motor drive and limit peripheral muscle fatigue development in humansThe Journal of Physiology, 2009